BioSpace News Archive

Evoke Pharma, Inc. announced that its real-world healthcare utilization data will be presented, as an oral plenary presentation, at the American College of Gastroenterology annual meeting taking place in Vancouver, BC, Canada from October 20-25, 2023.

Rapid and on-site diagnostic technologies for identifying and quantifying viruses are essential for planning treatment strategies for infected patients and preventing further spread of the infection.

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors effective October 4, 2023.

Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that it will exhibit at the Annual Association of Nurses in AIDS Care (ANAC) Conference.

Celularity Inc. announced that its Halal Certified biomaterial products have been classified by the Saudi Food and Drug Authority as “Minimally Manipulated Biological Products” for importation license purposes in the Kingdom of Saudi Arabia.

Meharry Medical College, along with partners Regeneron Genetics Center®, AstraZeneca, Novo Nordisk, and Roche, announced the launch of the Together for CHANGE™ initiative to create better health care and outcomes for all.

Results from a new obesity study conducted at Mayo Clinic to assess the utility of the Phenomix Sciences MyPhenome Hungry Brain test were presented at ObesityWeek 2023 by Mayo Clinic’s Dr. Diego Anazco, M.D., research postdoctoral fellow in the lab of Dr. Andres Acosta, M.D., Ph.D.

OncoNano Medicine, Inc. today announced it will be presenting positive preclinical data detailing delivery of interleukin-12 (IL-12) with the ON-BOARD™ platform at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 1-5, 2023 in San Diego, California.

Dynarex Corporation, a leading durable medical equipment and disposable medical products company, has honored Jamie Gray, Alabama State EMS Director, with the 2023 Dynarex EMS First Responder Caring Award.

Candel Therapeutics, Inc. today announced that Nature published results from the ongoing first-in-human phase 1 investigator-sponsored clinical trial of CAN-3110, a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate, in patients with recurrent high-grade glioma (HGG), of which 86.7% were glioblastoma, that had returned after standard of care (SoC) treatment.